1
|
Farnós O, Martins Fernandes Paes BC, Getachew B, Rourou S, Chaabene A, Gelaye E, Tefera TA, Kamen AA. Intranasally Delivered Adenoviral Vector Protects Chickens against Newcastle Disease Virus: Vaccine Manufacturing and Stability Assessments for Liquid and Lyophilized Formulations. Vaccines (Basel) 2023; 12:41. [PMID: 38250854 PMCID: PMC10819614 DOI: 10.3390/vaccines12010041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2023] [Revised: 12/08/2023] [Accepted: 12/20/2023] [Indexed: 01/23/2024] Open
Abstract
Newcastle disease (ND) remains a critical disease affecting poultry in sub-Saharan Africa. In some countries, repeated outbreaks have a major impact on local economies and food security. Recently, we developed an adenovirus-vectored vaccine encoding the Fusion protein from an Ethiopian isolate of Newcastle disease virus (NDV). The adenoviral vector was designed, and a manufacturing process was developed in the context of the Livestock Vaccine Innovation Fund initiative funded by the International Development Research Centre (IDRC) of Canada. The industrially relevant recombinant vaccine technology platform is being transferred to the National Veterinary Institute (Ethiopia) for veterinary applications. Here, a manufacturing process using HEK293SF suspension cells cultured in stirred-tank bioreactors for the vaccine production is proposed. Taking into consideration supply chain limitations, options for serum-free media selection were evaluated. A streamlined downstream process including a filtration, an ultrafiltration, and a concentration step was developed. With high volumetric yields (infectious titers up to 5 × 109 TCID50/mL) in the culture supernatant, the final formulations were prepared at 1010 TCID50/mL, either in liquid or lyophilized forms. The liquid formulation was suitable and safe for mucosal vaccination and was stable for 1 week at 37 °C. Both the liquid and lyophilized formulations were stable after 6 months of storage at 4 °C. We demonstrate that the instillation of the adenoviral vector through the nasal cavity can confer protection to chickens against a lethal challenge with NDV. Overall, a manufacturing process for the adenovirus-vectored vaccine was developed, and protective doses were determined using a convenient route of delivery. Formulation and storage conditions were established, and quality control protocols were implemented.
Collapse
Affiliation(s)
- Omar Farnós
- Viral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montreal, QC H3A 0G4, Canada (B.C.M.F.P.)
| | | | - Belayneh Getachew
- Research and Development Directorate, National Veterinary Institute, Bishoftu P.O. Box 19, Ethiopia (E.G.); (T.A.T.)
| | - Samia Rourou
- Laboratory of Molecular Microbiology, Vaccinology and Biotechnology Development, Group of Biotechnology Development, Institut Pasteur de Tunis, Université Tunis El Manar, 13, Place Pasteur. BP.74., Tunis 1002, Tunisia; (S.R.)
| | - Ameni Chaabene
- Laboratory of Molecular Microbiology, Vaccinology and Biotechnology Development, Group of Biotechnology Development, Institut Pasteur de Tunis, Université Tunis El Manar, 13, Place Pasteur. BP.74., Tunis 1002, Tunisia; (S.R.)
| | - Esayas Gelaye
- Research and Development Directorate, National Veterinary Institute, Bishoftu P.O. Box 19, Ethiopia (E.G.); (T.A.T.)
| | - Takele A. Tefera
- Research and Development Directorate, National Veterinary Institute, Bishoftu P.O. Box 19, Ethiopia (E.G.); (T.A.T.)
| | - Amine A. Kamen
- Viral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montreal, QC H3A 0G4, Canada (B.C.M.F.P.)
| |
Collapse
|
2
|
Islam EA, Fegan JE, Tefera TA, Curran DM, Waeckerlin RC, Ng D, Ahn SK, Lai CHR, Nguyen QH, Shah M, Tesfaw L, Adamu K, Medhin WW, Legesse A, Deresse G, Getachew B, Rawlyk N, Evans B, Potter A, Schryvers AB, Gray-Owen SD, Moraes TF. Reverse vaccinology-based identification of a novel surface lipoprotein that is an effective vaccine antigen against bovine infections caused by Pasteurella multocida. PLoS Pathog 2023; 19:e1011249. [PMID: 36961851 PMCID: PMC10075479 DOI: 10.1371/journal.ppat.1011249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2022] [Revised: 04/05/2023] [Accepted: 02/27/2023] [Indexed: 03/25/2023] Open
Abstract
Pasteurella multocida can infect a multitude of wild and domesticated animals, with infections in cattle resulting in hemorrhagic septicemia (HS) or contributing to bovine respiratory disease (BRD) complex. Current cattle vaccines against P. multocida consist of inactivated bacteria, which only offer limited and serogroup specific protection. Here, we describe a newly identified surface lipoprotein, PmSLP, that is present in nearly all annotated P. multocida strains isolated from cattle. Bovine associated variants span three of the four identified phylogenetic clusters, with PmSLP-1 and PmSLP-2 being restricted to BRD associated isolates and PmSLP-3 being restricted to isolates associated with HS. Recombinantly expressed, soluble PmSLP-1 (BRD-PmSLP) and PmSLP-3 (HS-PmSLP) vaccines were both able to provide full protection in a mouse sepsis model against the matched P. multocida strain, however no cross-protection and minimal serum IgG cross-reactivity was identified. Full protection against both challenge strains was achieved with a bivalent vaccine containing both BRD-PmSLP and HS-PmSLP, with serum IgG from immunized mice being highly reactive to both variants. Year-long stability studies with lyophilized antigen stored under various temperatures show no appreciable difference in biophysical properties or loss of efficacy in the mouse challenge model. PmSLP-1 and PmSLP-3 vaccines were each evaluated for immunogenicity in two independent cattle trials involving animals of different age ranges and breeds. In all four trials, vaccination with PmSLP resulted in an increase in antigen specific serum IgG over baseline. In a blinded cattle challenge study with a recently isolated HS strain, the matched HS-PmSLP vaccine showed strong efficacy (75-87.5% survival compared to 0% in the control group). Together, these data suggest that cattle vaccines composed of PmSLP antigens can be a practical and effective solution for preventing HS and BRD related P. multocida infections.
Collapse
Affiliation(s)
- Epshita A Islam
- Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada
| | - Jamie E Fegan
- Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
| | - Takele A Tefera
- Department of Veterinary Bacteriology, National Veterinary Institute, Bishoftu, Ethiopia
| | - David M Curran
- Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada
| | - Regula C Waeckerlin
- Department of Microbiology, Immunology, and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada
| | - Dixon Ng
- Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada
| | - Sang Kyun Ahn
- Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
| | - Chun Heng Royce Lai
- Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada
- Faculty of Dentistry, University of Toronto, Toronto, Ontario, Canada
| | - Quynh Huong Nguyen
- Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada
| | - Megha Shah
- Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada
| | - Liyuwork Tesfaw
- Department of Veterinary Bacteriology, National Veterinary Institute, Bishoftu, Ethiopia
| | - Kassaye Adamu
- Department of Veterinary Bacteriology, National Veterinary Institute, Bishoftu, Ethiopia
| | - Wubet W Medhin
- Department of Veterinary Bacteriology, National Veterinary Institute, Bishoftu, Ethiopia
| | - Abinet Legesse
- Department of Veterinary Bacteriology, National Veterinary Institute, Bishoftu, Ethiopia
| | - Getaw Deresse
- Department of Veterinary Bacteriology, National Veterinary Institute, Bishoftu, Ethiopia
| | - Belayneh Getachew
- Department of Veterinary Bacteriology, National Veterinary Institute, Bishoftu, Ethiopia
| | - Neil Rawlyk
- Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
| | - Brock Evans
- Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
| | - Andrew Potter
- Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
| | - Anthony B Schryvers
- Department of Microbiology, Immunology, and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada
| | - Scott D Gray-Owen
- Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
| | - Trevor F Moraes
- Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
3
|
Baziki JDD, Bodjo S. C, Nwankpa N, Maina N, Chitsungo E, Moustapha Boukary CR, A. Tefera T, Nwankpa RV, Mwangi N. Corrigendum to "Development and Evaluation of an Immuno-Capture Enzyme-Linked Immunosorbent Assay to Quantify the Mycoplasma capricolum subsp. Capripneumoniae (Mccp) Protein in Contagious Caprine Pleuropneumonia (CCPP) Vaccine". Vet Med Int 2021; 2021:9813273. [PMID: 33857268 PMCID: PMC8019645 DOI: 10.1155/2021/9813273] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2021] [Accepted: 03/17/2021] [Indexed: 11/25/2022] Open
Abstract
[This corrects the article DOI: 10.1155/2020/4236807.].
Collapse
Affiliation(s)
- Jean de Dieu Baziki
- African Union-Pan African Veterinary Vaccine Centre (AU-PANVAC), P.O. Box: 1746, Debre Zeit, Ethiopia
- Pan African University Institute for Basic Sciences, Technology and Innovation (PAUSTI), JKUAT Main Campus, P.O. Box: 62000-00200, Nairobi, Kenya
| | - Charles Bodjo S.
- African Union-Pan African Veterinary Vaccine Centre (AU-PANVAC), P.O. Box: 1746, Debre Zeit, Ethiopia
| | - Nick Nwankpa
- African Union-Pan African Veterinary Vaccine Centre (AU-PANVAC), P.O. Box: 1746, Debre Zeit, Ethiopia
| | - Naomi Maina
- Pan African University Institute for Basic Sciences, Technology and Innovation (PAUSTI), JKUAT Main Campus, P.O. Box: 62000-00200, Nairobi, Kenya
- Jomo Kenyatta University of Agriculture and Technology (JKUAT), P.O. Box: 62000-00200, Nairobi, Kenya
| | - Ethel Chitsungo
- African Union-Pan African Veterinary Vaccine Centre (AU-PANVAC), P.O. Box: 1746, Debre Zeit, Ethiopia
| | | | - Takele A. Tefera
- National Veterinary Institute, P.O. Box: 19, Debrezeit, Ethiopia
| | - Rume Veronica Nwankpa
- Addis Ababa University, Department of Microbial Cellular and Molecular Biology, P.O. Box: 1176, Addis Ababa, Ethiopia
| | - Nduta Mwangi
- Kenya Veterinary Vaccines Production Institute (KEVEVAPI), P.O. Box: 53260-00200, Nairobi, Kenya
| |
Collapse
|
4
|
Jean de Dieu B, Charles BS, Nwankpa N, Chitsungo E, Moustapha Boukary CR, Maina N, Tefera TA, Nwankpa RV, Mwangi N, Mathurin Koffi Y. Development and Evaluation of Epitope-Blocking ELISA for Detection of Antibodies against Contagious Caprine Pleuropneumonia in Goat Sera. Vet Sci 2019; 6:E82. [PMID: 31635322 PMCID: PMC6958372 DOI: 10.3390/vetsci6040082] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2019] [Revised: 09/06/2019] [Accepted: 09/07/2019] [Indexed: 12/28/2022] Open
Abstract
Enzyme linked immunosorbent assays (ELISAs) have been developed for the detection of antibodies against contagious caprine pleuropneumonia (CCPP), the causative agent of which is Mycoplasma capricolum subsp. Capripneumoniae (Mccp). The currently available commercial CCPP competitive ELISA (CCPP cELISA) kit produced and supplied by IDEXX Company (Westbrook, Maine, United States) is relatively expensive for most African laboratories. To address this issue and provide a variety of choices, a sensitive and specific blocking-ELISA (b-ELISA) test to detect antibodies against CCPP was developed. We describe the newly developed CCPP blocking-ELISA based on the blocking of an epitope of a monoclonal antibody (Mccp-25) by a positive serum sample against the Mccp protein coated on a plate. The Percentage Inhibition (PI) cut-off value for the CCPP b-ELISA was set at 50 using 466 CCPP negative and 84 CCPP positive small ruminant sera. Of the negative sera, 307 were obtained from the Botswana National Veterinary Laboratory (BNVL) and 159 from the Friedrich-Loeffler-Institute (FLI) Germany. The 84 positive sera samples came from experimentally vaccinated goats at the AU-PANVAC facility in Debre-Zeit, Ethiopia. The relative diagnostic sensitivity and specificity of the CCPP b-ELISA was 93% and 88%, respectively. This test result indicated good correlation with that of the commercial CCPP cELISA by IDEXX Company (Westbrook, Maine, United States) with a Cohen's κ agreement of κ agreement of 0.85. The newly developed CCPP b-ELISA will be useful in the detection of antibodies for the diagnosis CCPP and for sero-surveillance during vaccination campaigns.
Collapse
Affiliation(s)
- Baziki Jean de Dieu
- African Union-Pan African Veterinary Vaccine Centre (AU-PANVAC), P.O. Box 1746, Debrezeit, Ethiopia.
- Molecular Biology and Biotechnology Department, Pan African University Institute for Basic Sciences, Technology and Innovation (PAUSTI), JKUAT Main Campus, P.O. Box 62000-00200, Nairobi, Kenya.
| | - Bodjo S Charles
- African Union-Pan African Veterinary Vaccine Centre (AU-PANVAC), P.O. Box 1746, Debrezeit, Ethiopia.
| | - Nick Nwankpa
- African Union-Pan African Veterinary Vaccine Centre (AU-PANVAC), P.O. Box 1746, Debrezeit, Ethiopia.
| | - Ethel Chitsungo
- African Union-Pan African Veterinary Vaccine Centre (AU-PANVAC), P.O. Box 1746, Debrezeit, Ethiopia.
| | | | - Naomi Maina
- Molecular Biology and Biotechnology Department, Pan African University Institute for Basic Sciences, Technology and Innovation (PAUSTI), JKUAT Main Campus, P.O. Box 62000-00200, Nairobi, Kenya.
- Biochemistry Department, Jomo Kenyatta University of Agriculture and Technology (JKUAT), P.O. Box 62000-00200, Nairobi, Kenya.
| | - Takele A Tefera
- Research and Development Department, National Veterinary Institute, P.O. Box 19, Debrezeit, Ethiopia.
| | - Rume Veronica Nwankpa
- Department of Microbial Cellular and Molecular Biology, Addis Ababa University, P.O. Box 1176, Ethiopia.
| | - Nduta Mwangi
- Foot and Mouth Disease Department, Kenya Veterinary Vaccines Production Institute (KEVEVAPI), P.O. Box 53260-00200, Nairobi, Kenya.
| | - Yao Mathurin Koffi
- Laboratoire Central Veterinaire, Laboratoire de Virologie, B.P. 206 Bingerville, Côte d'Ivoire.
| |
Collapse
|